Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Omar Abdel-Rahman

Showing results (1-10 of 326) with videos related to

Pageof 33
Sort By:
American Journal of Clinical Oncology|December 18, 2020
Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER DatabaseOmar Abdel-Rahman
Clinical Breast Cancer|September 15, 2019
Impact of NCI Socioeconomic Index on the Outcomes of Nonmetastatic Breast Cancer Patients: Analysis of SEER Census Tract-Level Socioeconomic DatabaseOmar Abdel-Rahman
Clinical Genitourinary Cancer|March 19, 2017
Risk of Subsequent Primary Kidney Cancer After Another Malignancy: A Population-based StudyOmar Abdel-Rahman
The Clinical Respiratory Journal|November 9, 2017
Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysisOmar Abdel-Rahman
Future Oncology (London, England)|December 1, 2017
Dissecting the heterogeneity of stage III non-small-cell lung cancer through incorporation of grade and histologyOmar Abdel-Rahman
Immunotherapy|December 21, 2017
Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic reviewOmar Abdel-Rahman
Clinical Genitourinary Cancer|March 15, 2018
Revisiting the Prognostic Heterogeneity of AJCC Stage IV Carcinomas of the Upper Urinary TractOmar Abdel-Rahman
The Clinical Respiratory Journal|August 4, 2018
Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III studyOmar Abdel-Rahman
Future Oncology (London, England)|May 11, 2018
Dissecting the heterogeneity of localized prostate cancer risk groups through integration of percent of positive coresOmar Abdel-Rahman
Expert Opinion on Drug Safety|July 5, 2018
Predictors of skeletal-related events among cancer patients with bone metastases treated with zoledronic acid: a secondary analysis of a randomized studyOmar Abdel-Rahman
Pageof 33

Showing results (1-10 of 326) with videos related to

Sort By:
Pageof 33
American Journal of Clinical Oncology|December 18, 2020
Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER DatabaseOmar Abdel-Rahman
Clinical Breast Cancer|September 15, 2019
Impact of NCI Socioeconomic Index on the Outcomes of Nonmetastatic Breast Cancer Patients: Analysis of SEER Census Tract-Level Socioeconomic DatabaseOmar Abdel-Rahman
Clinical Genitourinary Cancer|March 19, 2017
Risk of Subsequent Primary Kidney Cancer After Another Malignancy: A Population-based StudyOmar Abdel-Rahman
The Clinical Respiratory Journal|November 9, 2017
Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysisOmar Abdel-Rahman
Future Oncology (London, England)|December 1, 2017
Dissecting the heterogeneity of stage III non-small-cell lung cancer through incorporation of grade and histologyOmar Abdel-Rahman
Immunotherapy|December 21, 2017
Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic reviewOmar Abdel-Rahman
Clinical Genitourinary Cancer|March 15, 2018
Revisiting the Prognostic Heterogeneity of AJCC Stage IV Carcinomas of the Upper Urinary TractOmar Abdel-Rahman
The Clinical Respiratory Journal|August 4, 2018
Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III studyOmar Abdel-Rahman
Future Oncology (London, England)|May 11, 2018
Dissecting the heterogeneity of localized prostate cancer risk groups through integration of percent of positive coresOmar Abdel-Rahman
Expert Opinion on Drug Safety|July 5, 2018
Predictors of skeletal-related events among cancer patients with bone metastases treated with zoledronic acid: a secondary analysis of a randomized studyOmar Abdel-Rahman
Pageof 33